Copyright
©2014 Baishideng Publishing Group Inc.
World J Pharmacol. Jun 9, 2014; 3(2): 24-32
Published online Jun 9, 2014. doi: 10.5497/wjp.v3.i2.24
Published online Jun 9, 2014. doi: 10.5497/wjp.v3.i2.24
Drug | Action | Dosing | Common side effects1 |
CBZ | Blocks Na+ and Ca2+ channels | 300-1000 mg; 100 mg BID initially, increase by 200 mg weekly Adequate trial 8-12 wk, 2 wk at maximal dose | Drowsiness, ataxia, headaches, nausea, vomiting, constipation, blurred vision, rash Drug interactions Taper doses when discontinuing |
OXC | Keto derivative of CBZ, same actions | Equivalent efficacy to CBZ; 300-2400 mg; 300 mg BID initially, increase by 600 mg weekly Adequate trial 8-12 wk, 2 wk at maximal dose | Improved tolerability compared to CBZ Vertigo, fatigue, dizziness, nausea, hyponatraemia in high doses No major drug interactions Taper doses when discontinuing |
TCAs or tricyclic antidepressants: nortriptyline, amitriptyline | Block NA and 5-HT reuptake, block Na+ channels, interact with several neurotransmitter systems | Nortriptyline 10 mg (elderly) or 25 mg (adult) at bedtime; increase dose by 10 or 25 mg every 3-7 d; up to 75-100 mg daily Adequate trial 6-8 wk, 2 wk at maximal dose Amitriptyline doses similar | Nortriptyline is better tolerated than amitriptyline Dry mouth, constipation, blurred vision, sedation, orthostatic hypotension Taper doses when discontinuing |
SNRIs or serotonin-noradrenaline reuptake inhibitors: Duloxetine, Venlafaxine | Similar actions to TCAs, but fewer interactions with receptor systems | Duloxetine: 60 mg/d, increase to 120 mg after 1 wk Venlafaxine: 75 mg/d, increase to 225 mg over 3 wk Adequate trial 4-6 wk, 2 wk at maximum dose | Headache, nausea, dry mouth, sleepiness, fatigue, constipation, dizziness, decreased appetite, and increased sweating. Taper doses when discontinuing Drowsiness, dizziness, weakness, feeling nervous, tinnitus, increased sweating, blurred vision, dry mouth, changes in appetite or weight, facial flushing, mild nausea, constipation, sexual side-effects Taper doses over 7-10 d when discontinuing |
Gabapentin | Ca2+ channel modulator | 100-300 mg TID, increase dose every 1-7 d; maximum dose 3600 mg daily Adequate trial 3-8 wk titration, 2-8 wk at maximal dose | Dizziness, sedation, weight gain, weakness, tiredness, nausea, diarrhea, constipation, blurred vision, headache, breast swelling, dry mouth, fatigue, myalgia, loss of balance or coordination Taper doses when discontinuing |
Pregabalin | Ca2+ channel modulator | 50 mg OD or 25 mg BID, double dose each week; maximum daily dose 600 mg Adequate trial is 4 wk at maximal dose | Dizziness, drowsiness, loss of balance or coordination, problems with memory or concentration, anxiety, depersonalization, hypertonia, hypesthesia, decreased libido, nystagmus, paresthesia, twitching, breast swelling, tremors, dry mouth, constipation Taper doses when discontinuing (minimum of one week) |
Tramadol | Inhibits NA and 5-HT reuptake, binds opioid receptors | 50 mg BID, increase by 50-100 mg daily in divided doses over 3-7 d as tolerated; 400 mg is maximum dose (300 mg in elderly) Adequate trial is 4 wk at maximum dose | Dizziness, spinning sensation, constipation, upset stomach, headache, drowsiness, feeling nervous or anxious |
Morphine | Interacts with mu opioid receptors in spinal cord and brain, regulates synaptic activity in pain pathways | 10-15 mg q4h or prn (equianalgesic doses for other opioids); after 1-2 wk, convert to long-acting opioid (e.g., CR hydromorphone) Titration allows for dose escalation Adequate trial is 4-6 wk | Sedation, pruritus, constipation, diarrhea, weight loss, nausea, vomiting, stomach pain, loss of appetite, flushing (warmth, redness, tingling), headache, dizziness, spinning sensation, memory problems, sleep problems (insomnia), strange dreams Taper doses when discontinuing |
- Citation: Hebb AL, Sawynok J, Bance M, Walling S, Chisholm K, Morris DP. Pharmacological management of neuropathic pain in patients with vestibular schwannomas: Experience of the Atlantic Lateral Skull Base Clinic. World J Pharmacol 2014; 3(2): 24-32
- URL: https://www.wjgnet.com/2220-3192/full/v3/i2/24.htm
- DOI: https://dx.doi.org/10.5497/wjp.v3.i2.24